Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aptevo Therapeutics Inc.APVO · Entity 8337 | Director | August 06, 2026 | August 11, 2026 |
| Emergent BioSolutions Inc.EBS · Entity 5902 | Director · CEO | March 04, 2019 | March 04, 2019 |
| REGENXBIO Inc.RGNX · Entity 2211 | Director | June 04, 2021 | June 08, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aptevo Therapeutics Inc.
Report date August 06, 2026 · Filed August 11, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 400 |
Reported balance
After 2026-08-06 transaction · row 1
1 source rowRow 1 · 2026-08-06 · Exercise / conversion · Acquired 400 · Balance 400 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-08-06 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-08-06 · Exercise / conversion · Disposed 400 · Balance 0 F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2: On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis.
F2: On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant.
Emergent BioSolutions Inc.
Report date March 04, 2019 · Filed March 04, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 142,617 |
Reported balance
After 2019-03-04 transaction · row 1
1 source rowRow 1 · 2019-03-04 · Sale · Disposed 14,565 · Balance 142,617 F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F2: The price reported is the weighted average price. These shares were sold in multiple transactions at prices ranging from $56.74 to $59.66, inclusive. |
| Common StockSEC Table I · non-derivative | IndirectBy Son | 1,936 |
Reported balance
Holding disclosure · report date 2019-03-04 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,936 F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi.
F2: The price reported is the weighted average price. These shares were sold in multiple transactions at prices ranging from $56.74 to $59.66, inclusive.
F3: The reporting person disclaims beneficial ownership of these securities, and this report shall not be deemed an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
REGENXBIO Inc.
Report date June 04, 2021 · Filed June 08, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $35.52 · Expires 2031-06-04 | Direct | 10,000 |
Reported balance
After 2021-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-04 · Grant · Acquired 10,000 · Balance 10,000 F1: The option will vest in 12 equal monthly installments following June 4, 2021. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in 12 equal monthly installments following June 4, 2021.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 11, 2026 01:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 400 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-343069 · ownership.xml · derivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant. F2 · derivative.expiration_date: On August 6, 2025, the reporting person was granted 7,200 (400 post-split) RSUs, vesting on the first anniversary of the date of grant. Read SEC document |
| August 06, 2026 Filed Aug 11, 2026 01:33 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-343069 · ownership.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 400 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 06, 2025 Filed Aug 8, 2025 20:36 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 7,200 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-105942 · ownership.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,200 Underlying: Common Stock · 7,200 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: The RSUs vest in full on the first anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vest in full on the first anniversary of the date of grant. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 20:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 1 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-097279 · ownership.xml · derivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On July 17, 2024, the reporting person was granted 925 (1 post-splits) RSUs, vesting in full one year from the date of grant. F2 · derivative.expiration_date: On July 17, 2024, the reporting person was granted 925 (1 post-splits) RSUs, vesting in full one year from the date of grant. Read SEC document |
| July 17, 2025 Filed Jul 21, 2025 20:41 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 1 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-25-097279 · ownership.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| July 17, 2024 Filed Jul 19, 2024 20:30 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 925 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-084944 · ownership.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 925 Underlying: Common Stock · 925 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: The RSUs vest in full on the first anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vest in full on the first anniversary of the date of grant. Read SEC document |
| June 02, 2024 Filed Jun 3, 2024 20:58 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 81 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-068070 · ownership.xml · derivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 81 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F4 · derivative.exercise_date: On June 2, 2023, the reporting person was granted 3,571 (81 post-split) RSUs, vesting in full on the first anniversary of the date of grant. F4 · derivative.expiration_date: On June 2, 2023, the reporting person was granted 3,571 (81 post-split) RSUs, vesting in full on the first anniversary of the date of grant. Read SEC document |
| June 02, 2024 Filed Jun 3, 2024 20:58 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 81 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-068070 · ownership.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 277 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · balance_after: On March 5, 2024, the Issuer effected a 1-for-44 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:58 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 7 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-068070 · ownership.xml · derivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: On June 1, 2021, the reporting person was granted 893 (20 post-split) RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022. F3 · derivative.expiration_date: On June 1, 2021, the reporting person was granted 893 (20 post-split) RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022. Read SEC document |
| June 01, 2024 Filed Jun 3, 2024 20:58 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 7 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950170-24-068070 · ownership.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 196 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · balance_after: On March 5, 2024, the Issuer effected a 1-for-44 reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 20:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 3,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-045294 · doc4.xml · derivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,571 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On August 9, 2022, the reporting person was granted 3,571 RSUs, vesting in full on the first anniversary of the date of grant. F2 · derivative.expiration_date: On August 9, 2022, the reporting person was granted 3,571 RSUs, vesting in full on the first anniversary of the date of grant. Read SEC document |
| August 09, 2023 Filed Aug 10, 2023 20:05 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 3,571 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-045294 · doc4.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| June 02, 2023 Filed Jun 2, 2023 20:43 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 3,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033830 · doc4.xml · derivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,571 Underlying: Common Stock · 3,571 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vest in full on the first anniversary of the date of grant. F3 · derivative.expiration_date: The RSUs vest in full on the first anniversary of the date of grant. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:43 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 297 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-033830 · doc4.xml · derivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 298 Underlying: Common Stock · 297 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On June 1, 2021, the reporting person was granted 893 RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022. F2 · derivative.expiration_date: On June 1, 2021, the reporting person was granted 893 RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022. Read SEC document |
| June 01, 2023 Filed Jun 2, 2023 20:43 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 297 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-033830 · doc4.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,768 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 20:09 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 3,571 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-045184 · doc4.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,571 Underlying: Common Stock · 3,571 shares Expires not disclosed F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: The RSUs vest in full on the first anniversary of the date of grant. F2 · derivative.expiration_date: The RSUs vest in full on the first anniversary of the date of grant. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 19:16 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionRestricted Stock Unit · Derivative | 298 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-033936 · doc4.xml · derivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 595 Underlying: Common Stock · 298 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. F2 · derivative.exercise_date: On June 1, 2021, the reporting person was granted 893 RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022. F2 · derivative.expiration_date: On June 1, 2021, the reporting person was granted 893 RSUs, vesting in three approximately equal annual installments beginning on June 1, 2022. Read SEC document |
| June 01, 2022 Filed Jun 3, 2022 19:16 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Exercise / conversionCommon Stock | 298 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-033936 · doc4.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,108 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted Stock Units ("RSUs") convert into common stock, $0.001 par value per share, of the Issuer on a one-for-one basis. Read SEC document |
| June 04, 2021 Filed Jun 8, 2021 20:13 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $35.52 | $0.00 |
DisclosureSEC source: 0001562180-21-004122 · primarydocument.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2031-06-04 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following June 4, 2021. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 23:32 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantRestricted Stock Unit · Derivative | 893 | $0.00 | $0.00 |
DisclosureSEC source: 0001019056-21-000353 · abdunnabi.xml · derivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 893 Underlying: Common Stock · 893 shares Expires not disclosed F2 · derivative.exercise_price: Restricted stock units (the "RSUs") convert into shares of the Issuer's common stock on a one-for-one basis. F3 · derivative.exercise_date: The RSUs vest in three approximately equal annual installments beginning on June 1, 2022. F3 · derivative.expiration_date: The RSUs vest in three approximately equal annual installments beginning on June 1, 2022. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 23:32 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 2,678 | $0.00 Strike: $26.15 | $0.00 |
DisclosureSEC source: 0001019056-21-000353 · abdunnabi.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,678 Underlying: Common Stock · 2,678 shares Expires 2031-06-01 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on June 1, 2022. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:11 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 170 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000433 · abdunnabi.xml · derivative · entry 5 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170 Underlying: Common Stock · 170 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F7 · derivative.exercise_date: These options will vest in three approximately equal annual installments beginning on the one year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:11 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 1,322 | Not disclosed Strike: $8.56 | Not disclosed |
DisclosureSEC source: 0001019056-20-000433 · abdunnabi.xml · derivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,322 Underlying: Common Stock · 1,322 shares Expires 2030-07-26 F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F6 · derivative.exercise_date: These options vest in full on the one year anniversary of the date of grant. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:11 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 1,785 | Not disclosed Strike: $76.86 | Not disclosed |
DisclosureSEC source: 0001019056-20-000433 · abdunnabi.xml · derivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,785 shares Expires 2028-06-01 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F5 · derivative.exercise_date: These options provide for vesting in three approximately equal annual installments beginning on May 31, 2019. Prior to July 27, 2020, all but 595 shares of the issuer's common stock underlying this stock option had vested. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:11 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 892 | Not disclosed Strike: $30.10 | Not disclosed |
DisclosureSEC source: 0001019056-20-000433 · abdunnabi.xml · derivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 892 shares Expires 2027-06-01 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F4 · derivative.exercise_date: These options vested in three approximately equal annual installments beginning on June 1, 2018. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 27, 2020 Filed Jul 30, 2020 01:11 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | Disposition to issuerStock Option (right to buy) · Derivative | 1,339 | Not disclosed Strike: $41.16 | Not disclosed |
DisclosureSEC source: 0001019056-20-000433 · abdunnabi.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,339 shares Expires 2026-08-03 F1 · derivative.exercise_price: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F1 · shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. F3 · price: In connection with the issuer's offer exchange program described in the issuer's tender offer statement on Schedule TO filed by the issuer with the Securities and Exchange Commission on June 29, 2020, as amended, on July 27, 2020 the issuer cancelled certain of the reporting person's options to acquire shares of the issuer's common stock and, in exchange thereof, granted the reporting person new options to acquire shares of the issuer's common stock, in each case, as reported on this Form 4. F2 · derivative.exercise_date: These options vested in three approximately equal annual installments beginning on August 3, 2017. F1 · derivative.underlying_shares: Reflects a 1-for-14 reverse stock split of the issuer's common stock effective as of March 26, 2020. Read SEC document |
| July 02, 2020 Filed Feb 18, 2021 01:59 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 3,571 | $0.00 Strike: $9.18 | $0.00 |
DisclosureSEC source: 0001019056-21-000139 · abdunnabi.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,571 Underlying: Common Stock · 3,571 shares Expires 2030-07-02 F1 · derivative.exercise_date: The option vests in three approximately equal annual installments beginning on July 2, 2021. Read SEC document |
| May 29, 2020 Filed Jun 2, 2020 20:30 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $37.66 | $0.00 |
DisclosureSEC source: 0001562180-20-004062 · primarydocument.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-05-29 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 29, 2020. Read SEC document |
| June 25, 2019 Filed Jun 25, 2019 23:11 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | PurchaseCommon Stock | 16,667 | $0.90 | $15,000.30 |
DisclosureSEC source: 0001593968-19-001480 · primary_01.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,351 Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 16:54 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantOption (right to buy) · Derivative | 25,000 | $0.00 Strike: $0.73 | $0.00 |
DisclosureSEC source: 0001593968-19-001273 · primary_01.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Aptevo Therapeutics Inc. common stock · 25,000 shares Expires 2029-06-01 F1 · derivative.exercise_date: The stock option was granted on June 1, 2019 and becomes exercisable in three equal annual installments beginning on June 1, 2020. Read SEC document |
| May 31, 2019 Filed Jun 4, 2019 20:16 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $43.02 | $0.00 |
DisclosureSEC source: 0001562180-19-003290 · primarydocument.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-05-31 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 31, 2019. Read SEC document |
| March 04, 2019 Filed Mar 4, 2019 23:39 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 14,565 | $58.11 | $846,328.46 |
DisclosureSEC source: 0001567619-19-006066 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 142,617 F1 · shares: The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F2 · price: The price reported is the weighted average price. These shares were sold in multiple transactions at prices ranging from $56.74 to $59.66, inclusive. Read SEC document |
| February 28, 2019 Filed Mar 1, 2019 00:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 5,101 | $58.71 | $299,479.71 |
DisclosureSEC source: 0001567619-19-005673 · doc1.xml · nonDerivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 157,182 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 27, 2019 Filed Mar 1, 2019 00:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 2,570 | $57.98 | $149,008.60 |
DisclosureSEC source: 0001567619-19-005673 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,283 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| February 26, 2019 Filed Mar 1, 2019 00:03 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 1,714 | $61.01 | $104,571.14 |
DisclosureSEC source: 0001567619-19-005673 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,853 F1 · security: Consists of restricted stock units granted under the company's stock incentive plan, as amended and restated. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:09 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,319 | $0.00 Strike: $13.38 | $0.00 |
DisclosureSEC source: 0001567619-18-002811 · doc1.xml · derivative · entry 7 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,319 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F4 · derivative.exercise_date: The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:09 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 1,319 | $65.00 | $85,735.00 |
DisclosureSEC source: 0001567619-18-002811 · doc1.xml · nonDerivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,567 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| September 17, 2018 Filed Sep 18, 2018 20:09 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 1,319 | $13.38 | $17,648.22 |
DisclosureSEC source: 0001567619-18-002811 · doc1.xml · nonDerivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 167,886 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 20:09 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 28,220 | $0.00 Strike: $13.38 | $0.00 |
DisclosureSEC source: 0001567619-18-002811 · doc1.xml · derivative · entry 6 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,319 Underlying: Common Stock · 28,220 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F4 · derivative.exercise_date: The option grant vested in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 20:09 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 28,220 | $65.00 | $1,834,300.00 |
DisclosureSEC source: 0001567619-18-002811 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,567 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| September 14, 2018 Filed Sep 18, 2018 20:09 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 28,220 | $13.38 | $377,583.60 |
DisclosureSEC source: 0001567619-18-002811 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 194,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| September 05, 2018 Filed Sep 6, 2018 21:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 30,776 | $59.49 | $1,830,944.26 |
DisclosureSEC source: 0001567619-18-002215 · doc1.xml · nonDerivative · entry 3 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,567 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F3 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.35 to $60.67, inclusive. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $13.38 | $0.00 |
DisclosureSEC source: 0001567619-18-002215 · doc1.xml · derivative · entry 5 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,539 Underlying: Common Stock · 60,000 shares Expires 2020-03-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · security: Consists of an option granted under the company's stock incentive plan as amended and restated. F6 · derivative.exercise_date: The option grant vests in three equal installments on the day prior to the first, second and third anniversary dates of the grant. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 60,000 | $60.54 | $3,632,286.00 |
DisclosureSEC source: 0001567619-18-002215 · doc1.xml · nonDerivative · entry 2 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,343 F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. F2 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.36 to $62.00, inclusive. Read SEC document |
| September 04, 2018 Filed Sep 6, 2018 21:51 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Exercise / conversionCommon Stock | 60,000 | $13.38 | $802,800.00 |
DisclosureSEC source: 0001567619-18-002215 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,343 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by Mr. Abdun-Nabi. Read SEC document |
| June 05, 2018 Filed Jun 7, 2018 21:07 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | SaleCommon Stock | 15,785 | $52.11 | $822,614.75 |
DisclosureSEC source: 0001140361-18-027713 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 197,343 F1 · price: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.83 to $52.66. inclusive. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 22:48 UTC | Aptevo Therapeutics Inc. APVO · Entity 8337 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $5.49 | $0.00 |
DisclosureSEC source: 0001019056-18-000778 · abdunnabi_4.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-05-31 F1 · derivative.exercise_date: The option vests in three equal annual installments beginning on May 31, 2019. Read SEC document |
| May 25, 2018 Filed May 30, 2018 20:25 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 12,500 | $0.00 Strike: $49.45 | $0.00 |
DisclosureSEC source: 0001562180-18-002713 · primarydocument.xml · derivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires 2028-05-25 F1 · derivative.exercise_date: The option will vest in 12 equal monthly installments following May 25, 2018. Read SEC document |
| March 09, 2018 Filed Mar 13, 2018 21:53 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 7,825 | $51.84 | $405,648.00 |
DisclosureSEC source: 0001140361-18-013315 · doc1.xml · nonDerivative · entry 1 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 213,128 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
| February 28, 2018 Filed Mar 1, 2018 22:01 UTC | Emergent BioSolutions Inc. EBS · Entity 5902 | Tax withholdingCommon Stock | 6,599 | $49.97 | $329,752.03 |
DisclosureSEC source: 0001140361-18-011280 · doc1.xml · nonDerivative · entry 4 Abdun-Nabi Daniel · CIK 0001380187 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,953 F1 · security: Consists of restricted stock units granted under the Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan, as amended. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.